Tenax Therapeutics Inc - Indikator likuiditas cepet TENX

Tenax Therapeutics (TENX) is shielded from price wars by its patents and orphan drug status, which create a long-term barrier to generics. The business is currently in the clinical trial stage, developing cutting-edge solutions for cardiology. The price action, where the indicator stands at 14.83, completes the picture of a company generating value through the therapy of right-heart pathologies and pulmonary hypertension.

For the biotechnology sector, where Tenax Therapeutics (TENX) invests in the development of the TNX-103 drug, the ability to fund clinical trials without selling long-term assets is critical. This quick ratio, which excludes inventories, is calculated as the ratio of cash and accounts receivable to current liabilities, confirming the company's financial stability in the face of potential liquidity gaps.